New drug combo aims to shrink Hard-to-Treat breast tumors before surgery
NCT ID NCT07618923
First seen Jun 02, 2026 · Last updated Jun 16, 2026 · Updated 2 times
Summary
This study tests a two-step treatment for people with a common type of breast cancer (HR+/HER2-low) that has a higher risk of coming back. First, patients take a daily pill (dalpiciclib) plus a hormone blocker for about 4 months, then receive an IV drug (SHR-A1811) every 3 weeks for another 3 months. The goal is to shrink tumors before surgery, and researchers will check how many patients have a complete or partial response. About 20 adults with stage II or III breast cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.